August 2013 , 14:P72 ,
Open Access This content is freely available online to anyone, anywhere at any time.
NO/cGMP/pCREB re-activation reverses cognition deficits and attenuates amyloid-β neuropathology in transgenic models of Alzheimer’s disease
Within this Article
- Background
- 作者单位：Gregory RJ Thatcher (130) (131)
Jia Luo (130) (132) (136)
Lawren VandeVrede (130)
Zhihui Qin (130)
Sue Lee (130)
Ramy Abdelhamid (130)
Brian M Bennett (133)
Mary Jo LaDu (134)
Leon Tai (134)
John Larson (135)
130. Department of Medicinal Chemistry & Pharmacognosy, University of Illinois College of Pharmacy, University of Illinois at Chicago (UIC), Chicago, IL, 60612, USA
131. UICentre (drug discovery @ UIC), UIC, Chicago, IL, 60612, USA
132. cGC Pharma Inc., Chicago, IL, USA
136. Cambridge, MA, 02142, USA
133. Department of Biomedical and Molecular Sciences, Faculty of Health Sciences, Kingston, Ontario, Canada
134. Department of Anatomy and Cell Biology, UIC, Chicago, IL, 60612, USA
135. Department of Psychiatry, Neuropsychiatric Institute, UIC, Chicago, IL, 60612, USA - ISSN：2050-6511
Results and Conclusion
文摘